MedTrace Logo

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

NCT05321498 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-09-28

No results posted yet for this study

Summary

The goal of this Phase 2 MCI study is to determine whether 1.0 mg/kg XPro1595 is superior to placebo at improving measures of cognition, functioning and brain quality in individuals with MCI and biomarkers associated with neuroinflammation (APOE4) and to evaluate safety, tolerability, and efficacy of XPro1595.

Conditions

Interventions

DRUG

XPro1595

XPro1595 will be delivered by subcutaneous injection once a week.

DRUG

Placebo

Placebo will be delivered by subcutaneous injection once a week

Sponsors & Collaborators

  • Inmune Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Tara Lehner · INmune Bio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2023-10-26
Completion
2023-10-26

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05321498 on ClinicalTrials.gov